Q3 2023 saw 3,866 therapies in development; 53% of those were gene therapies, 25% RNA therapies, and 22% non-genetically modified cell therapies.
The first Cell and Gene Therapy Regulatory Report from Citeline and ISCT provides a global overview of the cell and gene therapy landscape.
Europe’s drug innovative pipeline has reached a plateau, and is underexposed to high-growth areas such as oncology, cell and gene therapy.
